OBJECTIVES: To evaluate medication persistence in patients hypertensive chronic who have different percentages of financial subsidy in a Program Benefit Management (PBM). METHODS: We identified patients from 3 health care providers with different percentages of subsidy to buy a medication using the same service in PBM the first provider subsidizes 100%, the second subsidizes 90% (generic) and 70% (brand) and third subsidizes 40%. We selected patients with age ≥ 40 years male and female. The persistence analysis was made in the 12 months that followed from the first acquisition within the using method MPR (Medication Possession Ratio).The drugs was Antagonist of Angiotensin II Receptor (Losartan),Beta-Blocker (Atenolol), Calcium Channel Blocker (amlodipine) and an inhibitor of angiotensin converting enzyme (Enalapril). RESULTS: The persistence obtained with first provider (subsidizes 100%)  Amlodipine n=1266 and a persistence of 77.25%, n=1016 Atenolol and a persistence of 44.39%, n=680 and Enalapril a persistence of 90.00% and Losartan n=1157 and a persistence of 81.16% as an overall average of persistence between the four drugs was 73.20%, the second provider (subsidizes 90% for generic drugs and 70% for brand) obtained - Amlodipine n=1948 and a persistence of 78.49%, n=2061 Atenolol and a persistence of 32.07%, n=1265 Enalapril and persistence 84.19% of Losartan and n=2.166 and a persistence of 73.36% as an overall average of persistence between four drugs 67.03% and the third provider (subsidizes 40%), Amlodipine n=1264 and a persistence of 9.34%, n=1471 Atenolol and a persistence of 9.11%, n=941 Enalapril and a persistence of 36.88% and Losartan n=1917 and a persistence of 29.47% as a general average of persistence of the four 21.20% drugs. CONCLUSIONS: The average persistence varies statistically significantly with the percentage of subsidy the benefit influencing directly the persistence of these populations, the greater the allowance / benefit was greater at the rate of persistence between them.